Heart International最新文献_第7页

The Role of Rilonacept in Recurrent Pericarditis. 利洛纳肽在复发性心包炎中的作用。

IF 0.2

Heart International Pub Date : 2021-07-16 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.20

Saberio Lo Presti, Tarec K Elajami, Reza Reyaldeen, Chris Anthony, Allan L Klein

{"title":"The Role of Rilonacept in Recurrent Pericarditis.","authors":"Saberio Lo Presti, Tarec K Elajami, Reza Reyaldeen, Chris Anthony, Allan L Klein","doi":"10.17925/HI.2021.15.1.20","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.20","url":null,"abstract":"Recurrent pericarditis is associated with significant morbidity and adverse impact on quality of life. Contemporary studies have emphasized the key role of autoinflammatory pathways in its pathophysiology, mainly through the activation of inflammasomes and the production of interleukin (IL)-1α and IL-1β. The IL-1 pathway has emerged as a promising target for the treatment of these patients. A novel IL-1 inhibitor, rilonacept, functions as an IL-1 trap binding to the circulating IL-1α and IL-1β mitigating their inflammatory response. Recently, the RHAPSODY phase III clinical trial evaluated the use of rilonacept in patients with recurrent pericarditis, who were refractory to colchicine, or steroid-dependent. Rilonacept significantly reduced symptoms, inflammatory markers and recurrent episodes, and increased successful withdrawal of steroids. The safety profile of the medication is favourable and well tolerated by patients, with local injection site reaction being the most common side effect described. These results have shifted the paradigm of the understanding of the disease and promise to become part of the armamentarium of medications for the standard of care of these patients, with potential use as monotherapy. The changing landscape of therapeutics and pathophysiology warrants increased recognition and understanding from the international cardiology community about this novel drug and its implication in managing these complex patients.The objective of this review is to describe the bio-action of rilonacept in the treatment of recurrent pericarditis.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"20-25"},"PeriodicalIF":0.2,"publicationDate":"2021-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524724/pdf/heart-int-15-20.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia. 埃曲帕米鼻喷雾剂用于家庭治疗急性阵发性室上性心动过速的最新进展。

IF 0.2

Heart International Pub Date : 2021-07-15 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.2

Gavin S Chu, Dhiraj Gupta

引用次数: 2

Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review. 钠-葡萄糖共转运蛋白2抑制剂在心力衰竭治疗中的作用:临床综述

IF 0.2

Heart International Pub Date : 2021-07-15 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.42

Namit Rohant, Jamie Lw Kennedy

{"title":"Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.","authors":"Namit Rohant, Jamie Lw Kennedy","doi":"10.17925/HI.2021.15.1.42","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.42","url":null,"abstract":"Sodium-glucose cotransporter (SGLT) 2 inhibitors, or gliflozins, have quickly risen to prominence within the cardiovascular field due to their substantial benefit in the management of heart failure with reduced ejection fraction (HFrEF). SGLT channels are present throughout the body in various isoforms, but SGLT1 and SGLT2 have been the centre of medical investigation due to known genetic mutations. SGLT2 plays a major role in renal re-absorption of glucose, prompting the development of SGLT2 inhibitors to promote glycosuria and aid in diabetes management. The United States Food and Drug Administration requires evaluation of new antidiabetic medications for cardiovascular safety, prompting several randomized controlled trials of SGLT2 inhibitors over the past 5 years. These initial trials demonstrated superiority in cardiovascular outcomes with SGLT2 inhibitor use and suggested particular benefit in heart failure (HF) outcomes, prompting further study of their mechanisms. Subsequent SGLT2 inhibitor studies have demonstrated reductions in HF hospitalizations and cardiovascular mortality in patients with HFrEF, regardless of the presence of diabetes mellitus. In this review, we discuss the mechanism of action and major clinical trial results that have propelled SGLT2 inhibitors into a key role for patients with HFrEF.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"42-48"},"PeriodicalIF":0.2,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524703/pdf/heart-int-15-42.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer? 欧米伽 3 脂肪酸在心血管疾病中不断演变的作用：伊可新乙酯是答案吗？

IF 1.9

Heart International Pub Date : 2021-07-15 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.7

Suvasini Lakshmanan, Matthew J Budoff

{"title":"The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?","authors":"Suvasini Lakshmanan, Matthew J Budoff","doi":"10.17925/HI.2021.15.1.7","DOIUrl":"10.17925/HI.2021.15.1.7","url":null,"abstract":"Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality globally. Despite significant advances in pharmacotherapies and the beneficial effects of statin therapy on ASCVD outcomes and progression of atherosclerosis, residual cardiovascular (CV) risk remains. Extensive evidence has identified the contribution of atherogenic dyslipidaemia, which is particularly characterised by elevated triglycerides (TGL) as a key driver of CV risk, even if low-density lipoprotein cholesterol levels are well controlled. Epidemiologic and genetic/Mendelian randomisation studies have demonstrated that elevated TGL levels serve as an independent marker for an increased risk of ischaemic events, highlighting TGLs as a suitable therapeutic target. Clinical studies have shown that omega 3 fatty acids (OM3FA) are effective in lowering TGLs; however, to date, trials and meta-analyses of combined OM3FA products have not demonstrated any clinical CV outcome benefit in patients receiving statins. However, icosapent ethyl (IPE) - a highly purified, stable ethyl ester of eicosapentaenoic acid (EPA) - has been rigorously demonstrated in multiple studies to be a useful adjunctive therapy to address residual CV risk. EPA is an omega-3 polyunsaturated fatty acid that is incorporated into membrane phospholipid bilayers and is reported to exert multiple beneficial effects along the pathway of coronary atherosclerosis. In this brief review, we will provide an overview of the mode of action of IPE in coronary atherosclerosis, the robust clinical evidence and trial data supporting its use, and expert consensus/recommendations on its use in specific populations, as an adjunct to existing anti-atherosclerotic therapies.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"7-13"},"PeriodicalIF":1.9,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524612/pdf/heart-int-15-07.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40568365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions. 恶化心力衰竭的门诊管理:当前策略和未来方向。

IF 0.2

Heart International Pub Date : 2021-06-07 eCollection Date: 2021-01-01 DOI: 10.17925/HI.2021.15.1.49

Alison L Wand, Stuart D Russell, Nisha A Gilotra

{"title":"Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions.","authors":"Alison L Wand, Stuart D Russell, Nisha A Gilotra","doi":"10.17925/HI.2021.15.1.49","DOIUrl":"https://doi.org/10.17925/HI.2021.15.1.49","url":null,"abstract":"Heart failure (HF) is a highly prevalent and morbid disease in the USA. The chronic, progressive course of HF is defined by periodic exacerbations of symptoms, described as 'worsening heart failure' (WHF). Previously, episodes of WHF have required hospitalization for intravenous diuretics; however, recent innovations in care delivery models for patients with HF have allowed a transition from the acute care setting to the ambulatory setting. The development of remote monitoring strategies, including device-based algorithms and implantable haemodynamic monitoring systems, has facilitated more advanced surveillance of patients, aiming to prevent the clinical deterioration that leads to hospitalization. Additionally, the establishment of multidisciplinary HF clinics has provided the setting and resources for the outpatient treatment of WHF, specifically the administration of intravenous diuretics. Here we review the current state of ambulatory HF management, including mechanisms for patient monitoring and treatment, and outline future opportunities for outpatient management of this patient population.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"15 1","pages":"49-53"},"PeriodicalIF":0.2,"publicationDate":"2021-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524605/pdf/heart-int-15-49.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40583008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention. 叶轮支持的高危经皮冠状动脉介入治疗的出血风险综述。

IF 0.2

Heart International Pub Date : 2020-12-29 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.92

George W Vetrovec, Amir Kaki, Thom G Dahle

引用次数: 6

The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions. Myval经导管心脏瓣膜系统治疗严重主动脉瓣狭窄-目前的证据和未来的方向。

IF 0.2

Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.86

Gunasekaran Sengottuvelu, Vijay Kumar, Ashok Seth

引用次数: 4

Drug-coated Balloons or Drug-eluting Stents - Determining an Optimum Strategy for Patients with High Bleeding Risk. 药物涂层球囊或药物洗脱支架--为高出血风险患者确定最佳策略。

IF 1.9

Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.100

Natasha H Corballis, Tha H Nyi, Vassilios S Vassiliou, Simon C Eccleshall

引用次数: 0

Left Main Stenosis Stenting Normalises Wall Shear Stress of Ascending Aorta in Bicuspid Aortic Valve. 左主干狭窄支架置入使二尖瓣主动脉瓣升主动脉壁剪应力恢复正常。

IF 0.2

Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.121

Gianluca Rigatelli, Marco Zuin

{"title":"Left Main Stenosis Stenting Normalises Wall Shear Stress of Ascending Aorta in Bicuspid Aortic Valve.","authors":"Gianluca Rigatelli, Marco Zuin","doi":"10.17925/HI.2020.14.2.121","DOIUrl":"https://doi.org/10.17925/HI.2020.14.2.121","url":null,"abstract":"Introduction: Bicuspid aortic valve (BAV) is associated with dilation and dissection of the ascending aorta. The high shear forces within the ascending aorta lumen seem to have a pivotal role on the development of such complications. We describe the time-averaged wall shear stress (TAWSS) forces in a patient with normally functioning BAV and significant ostial/mid-shaft left main (LM) stenosis using computational fluid dynamic analysis (CFD).Case report: A 47-year-old female patient with normally functioning BAV with fusion of right and non-coronary cusps was investigated for unstable angina. CFD and stress mapping of the ascending aorta before LM stenting showed a mean TAWSS of 9.4 Pa and was associated with higher TAWSS values at the site of LM stenosis. The LM lesion was treated by stent implantation of an Orsiro (Biotronik, Berlin, Germany) 4.0 × 12 mm at 18 atm, preceded with a pre-dilation with non-compliant Euphora (Medtronic Inc., Santa Rosa, CA, USA) balloon 3.0 × 12 mm at 16 atm, and followed by an over-dilation with 4.5 × 12 mm non-compliant Euphora balloon at 20 atm. The reconstructed post-procedural model revealed a decrease of the mean ascending aorta TAWSS to 5.6 Pa.Conclusions: As suggested by our case, stenting of an LM lesion in a patient with BAV has the potential to improve the TAWSS in the ascending aorta, protecting the ascending aorta from the well-known complications of BAV.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 2","pages":"121-122"},"PeriodicalIF":0.2,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524745/pdf/heart-int-14-121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Quantification of Total Coronary Atheroma Burden - A Major Step Forward. 冠状动脉粥样硬化总负荷的量化——向前迈出的重要一步。

IF 0.2

Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI: 10.17925/HI.2020.14.2.73

Jean-Marc Foult, Shruthi Pranesh, Matthew J Budoff

{"title":"The Quantification of Total Coronary Atheroma Burden - A Major Step Forward.","authors":"Jean-Marc Foult, Shruthi Pranesh, Matthew J Budoff","doi":"10.17925/HI.2020.14.2.73","DOIUrl":"https://doi.org/10.17925/HI.2020.14.2.73","url":null,"abstract":"The extent of coronary artery disease has been shown to be an important indicator of prognosis. Cardiac computed tomography (CT) has the ability to measure plaque, with both coronary artery calcium scanning and CT angiography (CTA), to give a measure of total atheroma burden. Beyond assessing stenosis and atherosclerosis, CTA can assess high-risk plaque. These plaques are thought to be consistent with plaques that are vulnerable and more likely to rupture and cause acute coronary syndromes. However, the high-risk plaque concept suffers from poor reproducibility and poor positive predictive power. Total coronary atheroma burden has been shown to be a better predictor of coronary events than high-risk plaques or stenosis. This paper reviews the literature in this regard and demonstrates total coronary atheroma burden to be the best predictor of future cardiovascular disease. We searched MEDLINE, EMBASE and the Cochrane library database for studies assessing plaque burden and outcomes by CT. We used text words and related Medical Subject Headings (MeSH) for cardiac, calcification, plaque burden, CT, prognosis, mortality, event, death, survival and myocardial infarction.","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 2","pages":"73-75"},"PeriodicalIF":0.2,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524610/pdf/heart-int-14-73.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0